Pitt Shield

Ultrasound-mediated augmented exosome release from astrocytes alleviates amyloid-β-induced neurotoxicity.

Authors: Deng Z, Wang J, Xiao Y, Li F, Niu L, Liu X, Meng L, Zheng H

<b>Background:</b> Extracellular vesicles, including exosomes, are secreted by a variety of cell types in the central nervous system. Exosomes play a role in removing intracellular materials from the endosomal system. Alzheimer's disease (AD) is caused by an overproduction or reduced amyloid-beta (Aβ) peptide clearance. Increased Aβ levels in the brain may impair the exosome-mediated Aβ clearance pathway. Therapeutic ultrasound stimulation demonstrated its potential for promoting Aβ degradation efficiency in clinical trials. However, the underlying mechanism of ultrasound stimulation is still unclear. <b>Methods:</b> In this study, astrocytes, the most abundant glial cells in the brain, were used for exosome production. Post insonation, exosomes from ultrasound-stimulated HA cells (US-HA-Exo) were collected, nanoparticle tracking analysis and protein analysis were used to measure and characterize exosomes. Neuroprotective effect of US-HA-Exo in oligomeric Aβ<sub>42</sub> toxicated SH-SY5Y cells was tested. Cellular uptake and distribution of exosomes were observed by flow cytometry and confocal laser scanning microscopy. Focused ultrasound (FUS) with microbubbles was employed for blood-brain-barrier opening to achieve brain-targeted exosome delivery. After US-HA-Exo/FUS treatment, amyloid-β plaque in APP/PS1 mice were evaluated by Aβ immunostaining and thioflavin-S staining. <b>Results:</b> We showed that ultrasound resulted in an almost 5-fold increase in the exosome release from human astrocytes. Exosomes were rapidly internalized in SH-SY5Y cells, and colocalized with FITC-Aβ<sub>42</sub>, causing a decreased uptake of FITC-Aβ<sub>42</sub>. CCk-8 test results showed that US-HA-Exo could mitigate Aβ toxicity to neurons <i>in vitro</i>. The therapeutic potential of US-HA-Exo/FUS delivery was demonstrated by a decrease in thioflavin-S-positive amyloid plaques and Aβ immuno-staining, a therapeutic target for AD in APP/PS1 transgenic mice. The iTRAQ-based proteomic quantification was performed to gain mechanistic insight into the ultrasound effect on astrocyte-derived exosomes and their ability to alleviate Aβ neurotoxicity. <b>Conclusion:</b> Our results imply that US-HA-Exo have the potential to provide neuroprotective effects to reverse oligomeric amyloid-β-induced cytotoxicity <i>in vitro</i> and, when combined with FUS-induced BBB opening, enable the clearance of amyloid-β plaques <i>in vivo</i>.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To determine if ultrasound-stimulated astrocyte-derived exosomes can reduce amyloid-β toxicity in vitro and clear amyloid plaques in APP/PS1 mice when delivered with focused ultrasound-mediated BBB opening.
Animal model / Human subject Human astrocytes (HA cells) — species: Homo sapiens; strain: N/A; age: None; sex: None; SH-SY5Y cells (human neuroblastoma cell line) — species: Homo sapiens; strain: N/A; age: None; sex: None; APP/PS1 transgenic mice — species: Mus musculus; strain: APP/PS1 transgenic (background strain None); age: None; sex: None.
Disease model Alzheimer's disease
Cargo name and characteristics Ultrasound-stimulated human astrocyte-derived exosomes (US-HA-Exo): extracellular vesicle nanoparticles produced by HA cells after ultrasound stimulation, containing astrocyte proteins/biomolecules and used therapeutically to mitigate Aβ toxicity; also experimental use of oligomeric amyloid-β42 peptide (including FITC-labeled Aβ42) as a toxic/labeled peptide cargo in uptake and toxicity assays.

Outcomes and Safety

Summary of Outcomes Ultrasound stimulation of human astrocytes increased exosome release ~4–5-fold; these astrocyte-derived exosomes were rapidly taken up by neurons, reduced cellular uptake and toxicity of oligomeric Aβ42 in SH-SY5Y cells, and—when delivered to the brain via focused ultrasound (FUS) with microbubbles for BBB opening—significantly reduced Aβ immunostaining and thioflavin‑S-positive plaques in APP/PS1 mice. The study did not report testing multiple FUS parameter sets (only astrocyte insonation and FUS with microbubbles for BBB opening), so no distinct FUS parameter variations were identified as differentially successful.
Duration of biological effect 4 weeks
Safety-related matter No adverse effects were reported: H&E staining showed no brain tissue damage or hemorrhage from FUS-BBB opening, H&E of major organs after four weeks showed no damage, FUS-BBB opening was described as temporary, reversible and safe, and ultrasound treatment did not induce increased astrocyte proliferation.

Brain Region

Visualization unavailable

Ultrasound Parameters

Focal Characteristics focal depth: None, focal length: None, aperture size: None

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search